Loading organizations...

Key people at Neo Kuma Ventures.
Neo Kuma Ventures operates as a specialized venture capital firm, exclusively investing in early-stage psychedelic healthcare companies. It strategically backs entities engaged in clinical research, focusing on developing novel treatments with psychedelic compounds. This approach identifies and supports promising biotech and pharmaceutical ventures within an evolving therapeutic area.
Founded in 2020 by Clara Burtenshaw and Sean McLintock, Neo Kuma Ventures emerged from recognizing the nascent psychedelic medicine sector's potential. Identifying a critical need for dedicated capital to propel clinical research, the founders established Europe's first venture fund solely focused on psychedelic healthcare, fostering innovation with early-stage funding.
Portfolio companies develop solutions targeting mental health conditions like depression and PTSD. Through these investments, the firm aids the progression of new treatment paradigms offering breakthroughs for patients. Neo Kuma Ventures envisions cultivating a responsible, impactful psychedelic healthcare industry, contributing to enhanced global mental health.
Key people at Neo Kuma Ventures.
Neo Kuma Ventures is a London-based venture capital firm specializing in early-stage investments in psychedelic healthcare companies that are pioneering clinical research to address mental health conditions such as depression, PTSD, addiction, inflammation, and chronic pain. Their mission is to fund and support breakthrough psychedelic therapies that aim to redefine patient care by targeting the root causes of mental illness. They invest primarily from pre-seed to Series A rounds, with ticket sizes ranging from £150k to £1 million, focusing on compounds, clinics and care delivery, digital therapeutics, and platforms, mainly in Europe but with a global outlook[1][2][4].
Founded to back teams advancing psychedelic healthcare, Neo Kuma Ventures combines capital with deep sector expertise and a strong network built over 15 years. Their advisory board includes experienced partners from healthcare and venture capital backgrounds, such as Isabel Fox and Lomax Ward, who bring extensive knowledge in life sciences and healthcare investing. The firm emphasizes working closely with founders from the earliest stages to success, building an ecosystem that goes beyond funding to include strategic support and connections[1].
Neo Kuma Ventures is riding the wave of increasing scientific and regulatory acceptance of psychedelic therapies as viable treatments for mental health disorders. The timing is critical as mental health challenges grow globally and traditional treatments often fall short. Market forces such as rising mental health awareness, advances in clinical research, and shifting regulatory frameworks favor investment in this space. By funding pioneering companies, Neo Kuma Ventures helps accelerate the development and adoption of innovative therapies, influencing the broader healthcare ecosystem toward more effective mental health solutions[1][2].
Looking ahead, Neo Kuma Ventures is poised to capitalize on the expanding psychedelic healthcare market, which is expected to grow as clinical evidence and regulatory approvals increase. Their continued focus on early-stage investments and ecosystem support positions them to identify and nurture breakthrough companies that could transform mental health treatment. Trends such as digital therapeutics integration and personalized medicine will likely shape their portfolio’s evolution. As the sector matures, Neo Kuma Ventures’ influence may grow beyond capital provision to become a key driver of innovation and standard-setting in psychedelic healthcare[1][2].
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 7, 2023 | Syndi Health | $2.1M Grant / Pre-Seed | — | Damien Marmion, David Giampaolo, Jacob Haddad, James O’Shaughnessy, Phil Mohr, Puli Liyanagama, Roland Rudd, Stephen Bourke, Founders Factory, Innovate UK, Plug and Play, Remus Capital, Syndicate Room |
| Feb 26, 2022 | Fluence | $3.0M Seed | Simeon Schnapper, Neo Kuma Ventures, Palo Santo | Matthew Emerman, Michael Cotton, Noah Levy, Baroda Ventures, Evolve Ventures, Foundation Ventures, Iter Investments, LearnStart |
| Nov 1, 2021 | wavepaths | $5.0M Seed | — | 500 Global, Palo Santo VC, Sanjay Singhal, Charlie Hartwell, Empath Ventures, Adam Blackman, Lionheart Ventures, Miton, Reflex Capital, Tabula Rasa Ventures |
| Sep 1, 2021 | Journey Clinical | $3.0M Seed | Fifty Years | 2xN, Alumni Ventures, Beckley Waves, Founders Fund, Granite Asia, Kleiner Perkins, Mystic Ventures, PsyMed Ventures, Union Square Ventures, Dylan Field, Edvard Engesæth, Christina Sass, Edvard Engesæth, Hans Gangeskar, Lionheart Ventures, Palo Santo |